Kansas State logo.jpg
 

Bronze Sponsor

 

KSU presents Phoreus:

phoreus-biotech_KSU.jpg

Phoreus Biotechnology, Inc. is the exclusive licensee of the Branched Amphipathic Peptide Capsule (BAPC) platform technology from the Kansas State University Research Foundation. This novel nanomaterial comprised of natural biodegradable amino acids has the capacity to improve the delivery capabilities of new vaccines, cancer therapies, alternative antibiotics, agricultural biopesticides and diagnostics. BAPC is licensed by Phoreus for commercialization in plant protection and nutrition, veterinary and medical applications.
Privately held, the company is headquartered within the Kansas Bioscience Park in Olathe, Kansas.


 Randall Tosh   CEO, Phoreus Biotech

Randall Tosh

CEO, Phoreus Biotech

Special Content Session - University Showcase

Project: Branched Amphipathic Peptide Capsules (BAPC)

Phoreus Biotechnology has been granted exclusive worldwide license to the patented Branched Amphipathic Peptide Capsule (BAPC) technology. BAPC is a nanoparticle technology capable of improving delivery of gene-based applications, vaccines, therapeutics, pesticides, fungicides and plant nutrition. Many nanoparticle carriers are toxic to target cells limiting their use to basic research. In addition, most either lack stability, stimulate the immune system or are non-biodegradable. BAPC are self-assembling nanocarriers comprised of natural peptides. They are non-cytoxic, non-immunogenic, stable up to 100 Celsius and biodegradable. Phoreus is led by two KSU graduates with deep experience in agricultural sciences, veterinary medicine and business development.